- Home
- CODA vs ANVS Comparison
CODA vs ANVS Comparison
Compare CODA & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CODA | ANVS |
|---|---|---|
| Founded | 1994 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.4M | 111.3M |
| IPO Year | 2007 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CODA | ANVS |
|---|---|---|
| Price | $12.74 | $2.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | ★ 341.2K | 338.3K |
| Earning Date | 03-17-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 15.62 | ★ 39.39 |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $20,316,161.00 | N/A |
| Revenue This Year | $16.42 | N/A |
| Revenue Next Year | $14.43 | N/A |
| P/E Ratio | $161.88 | ★ N/A |
| Revenue Growth | ★ 4.98 | N/A |
| 52 Week Low | $5.76 | $1.11 |
| 52 Week High | $18.00 | $5.50 |
Technical Indicators
Market Signals| Indicator | CODA | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 44.56 | 49.37 |
| Support Level | $7.25 | $2.29 |
| Resistance Level | $14.89 | $2.63 |
| Average True Range (ATR) | 1.21 | 0.22 |
| MACD | -0.36 | 0.02 |
| Stochastic Oscillator | 4.40 | 44.73 |
Price Performance
Historical ComparisonAbout CODA Coda Octopus Group Inc.
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.